Advances in Biomarkers for CAR-T Treatment Resistance in Diffuse Large B-Cell Lymphoma
{{output}}
Chimeric antigen receptor (CAR)-T cell therapy has made significant progress in treating hematologic tumors, particularly diffuse large B-cell lymphoma (DLBCL). However, over 50% of patients are resistant after CAR-T cell therapy for DLBCL, and drug resistance... ...
